Anwaar Saeed, MD

Dr Saeed is an Assistant Professor of Medicine, Division of Medical Oncology, at the University of Kansas Cancer Center (KUCC). She is an active member and lead investigator in the Gastrointestinal (GI) Oncology program and the early phase developmental therapeutics program at the KUCC. She received her medical degree from the Arabian Gulf University-College of Medicine and Medical Sciences, Manama, Bahrain. She then completed an Internal Medicine residency at University of Missouri-Kansas City School of Medicine, Kansas City, MO followed by a hematology/oncology fellowship and GI oncology fellowship at the University of Kansas Medical Center, Kansas City, KS. Prior to joining the University of Kansas Cancer Center, she was an assistant professor at the University of Wisconsin Carbone Cancer Center in Madison, Wisconsin from 2014-2016. She is American Board certified in Internal Medicine, Hematology, and Medical Oncology.

Dr. Saeed's clinical research is focused on developmental therapeutics and immune modulatory approaches in patients with advanced gastric, esophageal, and colon cancer as well as chemoprevention in the high-risk GI population. She is leading the clinical research initiatives of novel therapeutics in these areas at KU Cancer Center. Driven by her interest in precision medicine and immuno-oncology, she has contributed and has been leading several ongoing translational projects evaluating various potential prognostic/predictive molecular markers in gastric, esophageal and colorectal cancer. She is a prolific clinical researcher and multiple award winner. Since joining KU Cancer Center in late 2016, she has been successful in securing multiple research grants to support several novel investigator-initiated clinical trials. Dr. Saeed is the KUCC Principal Investigator (PI) of the Academic GI Cancer Consortium (AGICC), a prestigious national organization that brings together renowned institutions and investigators to design and rapidly complete clinical trials in GI malignancies. She serves at the NCI Gastrointestinal Steering Committee Esophagogastric Task Force (EG TF). She is the study chair and national PI of an upcoming NCI cooperative group trial of a novel immunotherapy combination in patients with advanced gastric and gastroesophageal adenocarcinoma.

Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis

Association Between the Functional miR-146a SNP rs2910164 and Risk of Digestive System Cancer: Updated Meta-analysis

Association of losartan use with outcomes in metastatic pancreatic cancer patients treated with chemotherapy

Association of neutrophil, platelet, and lymphocyte ratios with prognosis in metastatic pancreatic cancer

Biologic and Immunotherapy Developments in Advanced Hepatocellular Carcinoma

Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma

Classifying inpatient deaths among liver and intrahepatic bile duct cancer and the effect of palliative care utilization on overall health care burden

Deaths among pancreatic cancer in-hospital, and the utilization of palliative care

Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer

Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

Preoperative Screening of Colorectal Cancers Is As Accurate As Postoperative Screening for Detection of Lynch Syndrome

Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications

Safety and Efficacy of Immune Checkpoint Inhibitor Re-challenge Following Immune-related Adverse Events: Systematic Review and Meta-analysis

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

Survival outcomes of Pancreatic intraepithelial neoplasm (PanIN) versus intraductal papillary mucinous neoplasm (IPMN) associated Pancreatic adenocarcinoma

The Duplex Interaction of Microbiome with Chemoradiation and Immunotherapy: Potential Implications for Colorectal Cancer

Treatment-related Adverse Events of Combination Immune Checkpoint Inhibitors Systematic Review and Meta-analysis

A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

A Phase II, Open-Label, Single-Arm Trial of [Fam]-Trastuzumab Deruxtecan (DS-8201a) in HER2-Positive, Unresectable and/or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed On or After A Trastuzumab-Containing Regimen

A Phase II trial of Cabozantinib in combination with Durvalumab in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies (CAMILLA) HSC#141879 (Investigator Initiated Trial)

A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME) (Investigator Initiated Trial)

A Randomized, Double-blind, Placebo-controlled Phase III Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

A021502 - RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR

MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)(Investigator Initiated Trial)

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors

Phase II pilot study of FOLFOXIRI plus panitumumab in metastatic RAS wild-type, left-sided colorectal cancer